Baxter Receives 510(k) Clearance From FDA For V-Link With VitalShield, New Antimicrobial Intravascular ...(are system states Dennis G. Maki MD Ovi...)

Date:11/9/2007

are system," states Dennis G. Maki, MD, Ovid O. Meyer Professor of Medicine at the University of Wisconsin School of Medicine and Public Health. "While adherence to basic infection control practices and procedures are essential, I believe that novel technologies for prevention are urgently needed to complement these efforts and reduce risk to the lowest levels possible."

About V-Link Luer-activated device with VitalShield protective coating

Many hospitalized patients need a steady supply of medications or fluids delivered into their blood stream. Typically, an IV catheter is placed in a patient's vein to allow direct access to the blood stream. In the process of injecting medications or fluids into a sterile line, surface or other environmental contaminants may be introduced. V-Link with VitalShield, a needleless IV connector used with the catheter or IV tubing, helps to prevent contamination and growth of pathogens on the device at this point of entry to the patient's blood stream. Reduction in colonization or microbial growth on the device has not been shown to correlate with a reduction in infections.

V-Link is uniquely coated on both inner and outer surfaces with a proprietary silver technology, called VitalShield. Silver is a well-known antimicrobial agent, and this specially designed formulation has been shown to be effective against a broad spectrum of microorganisms. The silver antimicrobial agent helps prevent the contamination and growth of these pathogens within the V-Link device. The antimicrobial agent is not intended to be used as a treatment for existing infections.

The V-Link LAD with VitalShield protective coating is the first introduction of Baxter's newly developed Vital Infusion Systems product line -- a new integrated portfolio of products developed to promote safety and reliability, and decrease risks associated with IV therapy.

About Healthcare-Associated Blood Stream Infections

Healthcare-associated infecti
'/>"/>

SOURCE Baxter Healthcare Corporation Copyright©2007 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3 4
Related biology technology :

1. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
2. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
3. Baxter Named to Dow Jones Sustainability Index for Ninth Consecutive Year
4. Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products
5. Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio
6. Baxter Kidney Patient Education Program Celebrates Tenth Anniversary
7. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
8. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
9. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
10. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
11. IsoTis Receives FDA Clearance for Accell Family of Products